Biohaven Ltd. (NYSE:BHVN) Holdings Increased by Suvretta Capital Management LLC

Suvretta Capital Management LLC increased its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 8.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,620,271 shares of the company's stock after buying an additional 421,052 shares during the period. Biohaven accounts for 7.2% of Suvretta Capital Management LLC's portfolio, making the stock its largest holding. Suvretta Capital Management LLC owned 5.56% of Biohaven worth $209,917,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Sphera Funds Management LTD. raised its stake in shares of Biohaven by 17.4% in the fourth quarter. Sphera Funds Management LTD. now owns 156,494 shares of the company's stock valued at $5,845,000 after purchasing an additional 23,171 shares in the last quarter. ProShare Advisors LLC raised its stake in Biohaven by 70.5% during the fourth quarter. ProShare Advisors LLC now owns 24,189 shares of the company's stock worth $903,000 after acquiring an additional 9,999 shares in the last quarter. Nuveen Asset Management LLC raised its stake in Biohaven by 55.1% during the fourth quarter. Nuveen Asset Management LLC now owns 919,235 shares of the company's stock worth $34,333,000 after acquiring an additional 326,636 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Biohaven by 32.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 54,271 shares of the company's stock worth $2,019,000 after acquiring an additional 13,147 shares in the last quarter. Finally, Lazard Asset Management LLC raised its stake in Biohaven by 47.4% during the fourth quarter. Lazard Asset Management LLC now owns 3,207 shares of the company's stock worth $119,000 after acquiring an additional 1,031 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

Insider Buying and Selling

In other news, Director John W. Childs acquired 32,700 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This trade represents a 1.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Robert W. Baird lowered their target price on Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a research note on Monday, April 28th. JPMorgan Chase & Co. cut their price objective on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the company a "buy" rating in a report on Thursday, March 20th. William Blair upgraded Biohaven to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Cantor Fitzgerald raised Biohaven to a "strong-buy" rating in a report on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $59.46.

Biohaven Stock Performance

Biohaven stock traded down $0.18 during mid-day trading on Thursday, reaching $15.53. The stock had a trading volume of 778,539 shares, compared to its average volume of 1,228,358. Biohaven Ltd. has a fifty-two week low of $14.69 and a fifty-two week high of $55.70. The stock's 50-day simple moving average is $21.52 and its 200-day simple moving average is $33.60. The firm has a market capitalization of $1.59 billion, a PE ratio of -1.66 and a beta of 1.18.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($2.17) EPS for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.50). On average, research analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.